Heparin Crisis Leads To New U.S. FDA Policy On Consulting Outside Experts
This article was originally published in PharmAsia News
Executive Summary
U.S. FDA's new policy for retaining outside experts in emergency situations calls for the agency to consider the risks posed by the collaboration as well as requirements for conflict-of-interest screening and disclosure